Jazz Pharmaceuticals (JAZZ) is trading higher as investors focus on upcoming oncology catalysts tied to the ASCO Annual Meeting (May 29–June 2, 2026, Chicago), where Jazz and partners plan multiple rapid oral and poster presentations spanning Ziihera (zanidatamab-hrii) in gastroesophageal adenocarcinoma and Zepzelca (lurbinectedin). The clustering of near-term conference visibility and anticipation of additional late-stage updates is helping support incremental buying interest in the stock. (investor.jazzpharma.com)

Sentiment has also been supported by recent sell-side positioning: Raymond James initiated (or resumed) coverage earlier in April with an Outperform rating and a $227 price target, reinforcing a valuation and pipeline-driven bull case into 2026. With the stock already having moved higher into late April, today’s gain appears consistent with continued follow-through from that constructive analyst backdrop alongside the conference countdown. (investing.com)

Key swing factors for the next several weeks are (1) the specific efficacy/safety details highlighted in the ASCO presentations for Ziihera in gastroesophageal adenocarcinoma, and (2) any incremental signals on Zepzelca’s durability and positioning in oncology. Any additional updates that clarify label expansion potential, sequencing, and commercial runway could amplify the move, while softer-than-expected details or heightened competition narratives could temper momentum. (investor.jazzpharma.com)